Posted by Michael Wonder on 04 Feb 2022
Samsung Bioepis announces Health Canada approval of 150 mg single-use vial and 440 mg multi-dose vial of Ontruzant (SB3), trastuzumab biosimilar for the treatment of adults with early breast cancer, metastatic breast cancer and metastatic gastric cancer
2 February 2022 - 150 mg and 440 mg vial of Ontruzant are now approved in Canada.
Samsung Bioepis today announced that Health Canada has approved Ontruzant (also known as SB3), a biosimilar referencing Herceptin (trastuzumab), for the treatment of adults with early breast cancer, metastatic breast cancer and metastatic gastric cancer.
